1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Drug Product Manufacturing
  6.  » Leveraging Proven Technology to Speed Path to First-In-Human Studies with GPEx® Lightning

Leveraging Proven Technology to Speed Path to First-In-Human Studies with GPEx® Lightning

Summary: With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 16 biopharmaceutical drugs using GPEx® cell line development technology and manufactured 45+ commercially approved products. Catalent recently introduced GPEx Lightning, a fast, flexible way to shorten the path to production of phase 1 material. During this talk, we share the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.

Click here to download the Webinar